Meregalli Mirella, Farini Andrea, Sitzia Clementina, Torrente Yvan
Stem Cell Laboratory, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Centro Dino Ferrari, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano Milano, Italy.
Front Physiol. 2014 Feb 12;5:48. doi: 10.3389/fphys.2014.00048. eCollection 2014.
Muscular dystrophies (MDs) are a heterogeneous group of inherited disorders, in which progressive muscle wasting and weakness is often associated with exhaustion of muscle regeneration potential. Although physiological properties of skeletal muscle tissue are now well known, no treatments are effective for these diseases. Muscle regeneration was attempted by means transplantation of myogenic cells (from myoblast to embryonic stem cells) and also by interfering with the malignant processes that originate in pathological tissues, such as uncontrolled fibrosis and inflammation. Taking into account the advances in the isolation of new subpopulation of stem cells and in the creation of artificial stem cell niches, we discuss how these emerging technologies offer great promises for therapeutic approaches to muscle diseases and muscle wasting associated with aging.
肌肉萎缩症(MDs)是一组遗传性疾病的统称,其特征为进行性肌肉萎缩和无力,常伴有肌肉再生潜能的耗尽。尽管骨骼肌组织的生理特性已为人熟知,但目前尚无有效的治疗方法。人们尝试通过移植成肌细胞(从成肌细胞到胚胎干细胞)以及干预病理组织中发生的恶性过程(如不受控制的纤维化和炎症)来实现肌肉再生。考虑到在分离新的干细胞亚群以及创建人工干细胞微环境方面所取得的进展,我们讨论了这些新兴技术如何为治疗肌肉疾病以及与衰老相关的肌肉萎缩带来巨大的治疗前景。